← back to search

Gunnar Cario

University Hospital Heidelberg · DE
Area of research
Public Health, Environmental and Occupational Health · Hematology
Research interest
Research interests include Medicine, Internal medicine, Lymphoblastic Leukemia, Oncology, Biology, and Cancer research.
h-index
citations
2,830
works
58
NIH funding
primary concept
email

Recent publications

Intra‐subtype heterogeneity shapes treatment response in <i>KMT2A</i> ‐rearranged ALL across all age groups
HemaSphere 2026cited by 1position: middledoi
Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
Journal of Hematology & Oncology 2025cited by 5position: middledoi
NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation
Blood 2025cited by 4position: middledoi
Subclonal <i>TP53</i> and <i>KRAS</i> variants combined with poor treatment response identify ultrahigh-risk pediatric patients with T-ALL
Blood Advances 2025cited by 3position: middledoi
Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: a nationwide population-based registry analysis
The Lancet Regional Health - Europe 2025cited by 2position: middledoi
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial
The Lancet Oncology 2024cited by 20position: middledoi
An artificial intelligence-assisted clinical framework to facilitate diagnostics and translational discovery in hematologic neoplasia
EBioMedicine 2024cited by 12position: middledoi
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukaemia in children and young adults
Haematologica 2024cited by 4position: middledoi
High Parathyroid Hormone Rather than Low Vitamin D Is Associated with Reduced Event-Free Survival in Childhood Cancer
Cancer Epidemiology Biomarkers & Prevention 2024cited by 2position: middledoi
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
Blood Advances 2023cited by 55position: middledoi
The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age
HemaSphere 2023cited by 53position: middledoi
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
Journal of Clinical Investigation 2023cited by 39position: middledoi
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial
The Lancet Haematology 2023cited by 39position: middledoi
Developmental trajectories and cooperating genomic events define molecular subtypes of <i>BCR</i>::<i>ABL1</i>-positive ALL
Blood 2023cited by 26position: middledoi
Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group
Journal of Experimental & Clinical Cancer Research 2023cited by 7position: middledoi
Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction
HemaSphere 2023cited by 5position: middledoi
The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome
Leukemia 2023cited by 3position: middledoi
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease
Leukemia 2022cited by 57position: lastdoi
Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution
Leukemia 2022cited by 17position: middledoi
Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
Nature Medicine 2021cited by 166position: middledoi
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium
Blood 2021cited by 72position: middledoi
The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia
Cancers 2021cited by 59position: middledoi
Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome
Bone Marrow Transplantation 2021cited by 41position: middledoi
MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia
Blood 2021cited by 23position: middledoi
Publisher Correction: Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
Nature Medicine 2021cited by 4position: middledoi
Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study
The Lancet Haematology 2020cited by 65position: middledoi
Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia
Annals of Hematology 2020cited by 42position: middledoi
Chromatin accessibility landscape of pediatric T‐lymphoblastic leukemia and human T‐cell precursors
EMBO Molecular Medicine 2020cited by 27position: middledoi
Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia
Haematologica 2020cited by 19position: middledoi
MondoA Drives Malignancy in cALL through Enhanced Adaptation to Metabolic Stress
bioRxiv (Cold Spring Harbor Laboratory) 2020cited by 1position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Martin Schrappe · University Hospital and Clinics29 papers (2012–2025)Martin Stanulla · Medizinische Hochschule Hannover24 papers (2012–2025)Cornelia Eckert · Deutschen Konsortium für Translationale Krebsforschung16 papers (2013–2025)Jean‐Pierre Bourquin · Novartis (Switzerland)12 papers (2016–2025)Joachim B. Kunz · Heidelberg University10 papers (2016–2025)Gabriele Escherich · Universität Hamburg10 papers (2017–2025)Andreas E. Kulozik · German Cancer Research Center10 papers (2016–2025)Renate Kirschner‐Schwabe · Krankenhaus St. Joseph-Stift Bremen9 papers (2017–2022)Martina U. Muckenthaler · University Medical Centre Mannheim9 papers (2016–2023)Jan O. Korbel · Eppendorf (Belgium)9 papers (2016–2025)Martin Zimmermann · Medizinische Hochschule Hannover9 papers (2012–2024)Paulina Richter‐Pechańska · Charité - Universitätsmedizin Berlin9 papers (2016–2025)Martin Zimmermann · Medizinische Hochschule Hannover9 papers (2018–2025)Anja Möricke · Clinical Research Center Kiel8 papers (2012–2023)Beat Bornhäuser · Novartis (Switzerland)8 papers (2016–2022)Julia Alten · Friedrich-Alexander-Universität Erlangen-Nürnberg8 papers (2017–2025)Tobias Rausch · Genomics (United Kingdom)8 papers (2017–2025)Giovanni Cazzaniga · Novartis (Switzerland)7 papers (2012–2023)Arend von Stackelberg · Charité - Universitätsmedizin Berlin7 papers (2016–2025)Andishe Attarbaschi · University of Padua7 papers (2012–2025)